Sana Biotechnology, Inc.於2018年7月13日在特拉華州註冊成立。該公司正在開發離體和體內細胞工程平台，以徹底改變一系列尚未滿足治療需求的治療領域，包括腫瘤學、糖尿病、中樞神經系統疾病、心血管疾病和遺傳疾病等。預計該公司的第一個項目，即CD19靶向異體嵌合抗原受體（CAR）T（SC291）項目的臨床數據將在2023年發布。該公司還在開發細胞工程平台方面取得進展，並通過臨床前開發推進候選產品，目標是在2023年及以後提交多個研究性新藥。
董事
名稱
職位
Hans Bishop
Chairman of the Board
Richard C. Mulligan
Head of SanaX and Executive Vice-Chairman
Steven D. Harr
President, Chief Executive Officer, and Director
Alise S. Reicin
Director
Douglas Cole
Director
Geoffrey von Maltzahn
Director
Joshua H. Bilenker
Director
Mary Agnes Wilderotter
Director
Michelle Seitz
Director
Patrick Yang
Director
Robert Taylor NELSEN
Director
股東
名稱
職位
Steven D. Harr
President, Chief Executive Officer, and Director
Christian Hordo
Senior Vice President, Chief Business Officer
Nathan Hardy
Senior Vice President, Chief Financial Officer
James J. MacDonald
Executive Vice President, General Counsel, and Corporate Secretary
Richard C. Mulligan
Head of SanaX and Executive Vice-Chairman
Sunil Agarwal
Executive Vice President, Head of Development and Chief Medical Officer